Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
-New threshold of 3% to be reported under Stock Exchange Act-
Basel/Switzerland and Bridgewater NJ/USA, 4 February 2008
Speedel Holding Ltd (SWX: SPPN) today announced a significant
shareholding in accordance with article 20 of the Swiss Federal Act
on Stock Exchanges and Securities Trading (SESTA) which introduced a
new threshold of 3% in December 2007.
Consequently, the following is disclosed as the holding exceeds 3%.
Holder: Perutil S.A., Calle Aquilino de la Guardia No 8, Edificio
IGRA No. 201, P.O. Box 0823-04699, Panama, Republic of Panama
Number of shares held: 305,000
% of voting rights: 3.979%
The threshold value is calculated on the basis of the total number of
voting rights as per the entry in the commercial register.
About Speedel
Speedel is a public biopharmaceutical company that seeks to create
value for patients, partners and investors by developing innovative
therapies for cardiovascular and metabolic diseases. Speedel is a
world leader in renin inhibition, a promising new approach with
significant potential for treating cardiovascular diseases. Our lead
compound SPP100 (Tekturna/Rasilez[i][1]), the first-in-class direct
renin inhibitor, was in-licensed from Novartis in 1999 and
licensed-back to Novartis Pharma in 2002 for further development and
commercialisation; SPP100 was approved by the FDA in the US in March
2007, and filed by Novartis with the EMEA in the EU in Q3 2006. Our
pipeline covers three different modes of action, and in addition to
SPP100, includes SPP301 in Phase II, SPP200 in Phase II, SPP635 in
Phase Il, SPP1148 in Phase I, SPP676 in Phase I and several
pre-clinical projects.
Speedel develops novel product candidates through focused innovation
and smart drug development from lead identification to the end of
Phase II. We either partner with big pharma for Phase III and
commercialisation in primary-care indications, or we may ourselves
complete Phase III development in specialist indications. Candidate
compounds for development and the company's intellectual property
come from our late-stage research unit Speedel Experimenta and from
in-licensing. Our team of approximately 80 employees, including over
30 experienced pharmaceutical scientists, is located at our
headquarters and laboratories in Basel, Switzerland and at offices in
New Jersey, USA and Tokyo, Japan.
In January 2007 the company raised gross proceeds of CHF 55.5 million
(approximately EUR 34.3 million or USD 44.5 million) through a
convertible bond issue. In March 2006 the company raised gross
proceeds of CHF 83.95 million (approximately EUR 53m or USD 64m)
through the public offering of 500,000 treasury shares. Previously,
as a private company, we raised gross proceeds of CHF 255 million
(approximately EUR 157 million or USD 204 million) from private
placements of equity securities and two convertible loans including
the conversion premiums. We have had total revenues, principally from
milestone payments, of CHF 57.7 million (approximately EUR 37 million
or USD 44 million). The company's shares were listed in September
2005 on the SWX Swiss Exchange under the symbol SPPN.
Forward looking statements
This press release includes forward-looking statements that involve
substantial risks and uncertainties. These forward-looking statements
are based on our current expectations and projections about future
events. All statements, other than statements of historical facts,
regarding our strategy, future operations, future financial position,
future revenues, projected costs, prospects, plans and objectives of
management are forward-looking statements. The word "may" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. We may not actually achieve the plans, intentions or
expectations described in these forward-looking statements and you
should not place undue reliance on them. There can be no assurance
that actual results of our research and development activities and
our results of operations will not differ materially from these
expectations. Factors that could cause actual results to differ from
expectations include, among others: our or our partners' ability to
develop safe and efficacious products; our or our partners' ability
to achieve positive results in clinical trials; our or our partners'
ability to obtain marketing approval and market acceptance for our
product candidates; our ability to enter into future collaboration
and licensing agreements; the impact of competition and technological
change; existing and future regulations affecting our business;
changes in governmental oversight of pharmaceutical product
development; the future scope of our patent coverage or that of third
parties; the effects of any future litigation; general economic and
business conditions, both internationally and within our industry,
including exchange rate variations; and our future financing plans.
-- Ends --
[1] Tekturna/ Rasilez ® are Novartis trademarks
For further information please contact
Nick Miles
Director Communications & Investor Relations
Speedel
Hirschgässlein 11
CH - 4051 Basel
Switzerland
T +41 (0) 61 206 40 00
D +41 (0) 61 206 40 14
F +41 (0) 61 206 40 01
M +41 (0) 79 446 25 21
E nick.miles@speedel.com
www.speedel.com
Frank LaSaracina
Managing Director
Speedel Pharmaceuticals Inc
1661 Route 22 West
P.O. Box 6532
Bridgewater, NJ 08807
United States of America
T +1 732 537 2290
F +1 732 537 2292
M +1 908 338 0501
E frank.lasaracina@speedel.com
www.speedel.com
--- End of Message ---
Speedel Holding AG
Hirschgässlein 11 Basel
ISIN: CH0021483885;
Index: SPI, SPIEX, SBIOM, SLIFE, SSCI;
Listed: Main Market in SWX Swiss Exchange;
